MSB 1.49% $1.02 mesoblast limited

Ann: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L, page-157

  1. 7,543 Posts.
    lightbulb Created with Sketch. 6810
    Come on @Zenox, with all due respect, you are a better poster than that. The FDA did not "require" another RCT, they "recommended" one. Big difference.

    (see the original CRL advice of October 2020)
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.